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Background.  Many parasitic infections have different presenting features in endemic 
populations and immunologically naïve temporary residents.  Prior studies describe a 
clinical syndrome characterized by dramatic acute symptoms and hypereosinophilia in 
travelers infected with the filarial parasite Loa loa, in contrast to a parasite-induced 
subclinical (asymptomatic) state in chronically infected endemic hosts.  Few studies have 
examined the relationship between endemicity and disease manifestations in other filarial 
infections.  We aim to directly compare the clinical characteristics and laboratory 
findings in endemic individuals (END) and temporary residents (TR) infected with the 
filarial parasite Onchocerca volvulus. 
Methods.  We identified all patients definitively diagnosed with active Onchocerca 
volvulus infection at the National Institutes of Health between 1976 and 2016.  All study 
subjects received a detailed baseline assessment including a comprehensive history, 
physical examination, ophthalmologic evaluation, and extensive laboratory investigations 
including testing for parasitic coinfections.  We performed additional parasite-specific 
serologic testing on stored patient sera. 
Results.  Forty temporary residents (TR) and 36 endemic subjects (END) had active 
onchocerciasis.  All END patients were symptomatic, whereas 12.5% of TR reported no 
O. volvulus symptoms (P = .06).  Papular dermatitis was more common in TR (47.5% vs 
2.7%, P < .001), while pigmentation changes were more often observed in END (41.7% 
vs 15%, P = .01).  Only END patients reported visual disturbance (13% vs 0%, P = .03).  
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Onchocercal eye disease was detected in 22.6% of END patients and in only 1 TR (3.3%, 
P = .053).  There was no difference in baseline eosinophil levels between groups (P = .5), 
and one third of subjects in both groups had a normal eosinophil count.  END patients 
had higher filarial-specific IgG4 levels and were more likely to be positive for IgG4 
antibodies to OV16.  
Conclusions.  Although there is substantial overlap in the presentation of O. volvulus 
infection in TR and END populations, skin manifestations differed, and ocular 
involvement was almost exclusively observed in END patients.  Unlike Loa loa, 
differences in clinical presentation do not appear to be eosinophil-mediated, and instead 
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Onchocerciasis is a neglected tropical disease caused by the filarial parasite 
Onchocerca volvulus, that can lead to chronic debilitating skin and eye pathology.  At 
least 18 million people are infected, and 180 million live in at-risk areas worldwide.[1,2]  
Also known as “river blindness”, onchocerciasis is the second leading infectious cause of 
blindness, and is responsible for 270,000 cases of blindness and 500,000 cases of visual 
impairment worldwide.[3–5]  
Chronic skin and eye disease caused by O. volvulus has many devastating long-
term socioeconomic consequences.  Visual impairment due to onchocerciasis historically 
occurred in up to 40% of adults in hyperendemic areas, ultimately driving population 
migration to lower transmission zones and away from arable land.[5]  In comparison to 
healthy individuals, those affected by onchocercal dermatitis or visual impairment have 
substantially lower economic productivity examining a variety of measures, including 
income, ability to maintain employment, length of workday, and ability to concentrate at 
work.[6]  In 2015, onchocerciasis resulted in the loss of an estimated 1.1 million 
disability adjusted life years (DALYs), an age-standardized DALY rate of 15.5 per 
100,000.[7]  Current estimates likely underrepresent the true disease burden and 
population impact, due to sparse epidemiologic data in the remote areas of sub-Saharan 
Africa where the disease is most prevalent.[8–10] 
Onchocerciasis is currently endemic in 31 countries in Africa, which harbours 
over 95% of global disease.[1]  Limited foci of active transmission still exist in Yemen, 
Venezuela and Brazil, in the wake of successful elimination campaigns in previously 
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endemic Latin American countries including Colombia, Ecuador, Mexico, and most 
recently Guatemala as of July, 2016.[1,11]  Onchocerciasis control and elimination 
programs have dramatically reduced global disease burden through mass drug 
administration with ivermectin, and aerial insecticide spraying.  The disease almost 
exclusively affects rural populations living in poverty, as the Simulium blackfly vector 
reproduces near remote fast-flowing rivers and streams.  Infected blackflies have a 
limited flight range and typically bite humans while accessing fresh water for washing, 
bathing, and agricultural or occupational use.[12]  
Humans are the only host for O. volvulus.  Simulium blackflies inoculate third-
stage (L3) larvae into human skin, where they penetrate deeper subcutaneous tissues and 
mature into adult worms over 6-12 months.  Adults coalesce into fibrous nodules termed 
“onchocercomata”, and each adult female typically releases 1,000-3,000 immature larvae 
(microfilariae) each day.[4]  Adult worms will ultimately produce millions of 
microfilariae over the course of their 9-15 year lifespan.[4,9]  Microfilariae migrate 
throughout the skin, eyes, and lymphatics, and survive for 6 to 24 months.[4,5]  
Blackflies, in turn, ingest dermal microfilariae, which then mature into L3 larvae in the 
arthropod vector as O. volvulus completes its lifecycle.  The commensal intracellular 
bacteria Wolbachia can be found in all life cycle stages and plays an essential role in 
embryogenesis and parasite survival.[4,13] 
 O. volvulus causes human disease by inducing an inflammatory immune response 
to dying microfilariae in host tissues, leading to tissue damage as a byproduct.[5]  Live 
migrating microfilariae do not appear to provoke a significant inflammatory response, but 
rather it is the release of antigen from both dying microfilariae and endosymbiotic 
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Wolbachia that leads to immune activation and inflammation.[4,13–15]  An extreme 
illustration of this is the Mazzotti reaction, in which treatment with diethylcarbamazine 
rapidly kills microfilariae, and in doing so provokes potentially life-threating acute 
hypotension, tachycardia, pruritus, adenitis, arthralgia, and ocular inflammation.[16] Both 
the Mazzotti reaction and more moderate post-treatment reactions occurring after the first 
dose of ivermectin are associated with the release of intracellular Wolbachia.[15,17]  In 
the natural course of infection, between 20,000 to 500,000 microfilariae die each day 
depending on the burden of infection, leading to significant chronic inflammation.[5]  
There is a substantial time-lag between infection and symptom onset, which likely 
reflects the parasite’s long pre-patent period of 7 months to 2 years.[18–20]  Microfilariae 
are not typically detected in skin until 10-15 months after initial infection.  The most 
common symptom of onchocerciasis is generalized pruritus, which ranges in severity 
from mild to unrelenting distressing itch.[21]  Severe pruritus and dermatitis affect 6.5 
million people with the disease, and can be disabling to the point of causing constant 
distress, interference with work and sleep, and even social stigmatization due to skin 
disfigurement.[5,18,22]  In endemic communities, 40% of adults report troublesome 
itch.[21]  A myriad of skin manifestations may occur in Onchocerca infection, and 
include papular rash, lichenification, hyper or hypopigmentation, and epidermal 
atrophy.[5,21]  Onchocercal eye disease can occur in either the anterior or posterior 
chambers, and can present as uveitis, chorioretinitis, optic neuritis and punctate keratitis.  
Early corneal involvement is potentially reversible, however untreated eye disease may 
progress to fibrosing/sclerosing keratitis or optic nerve atrophy leading to permanent 
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visual impairment.[23]  Other disease manifestations include lymphedema, 
lymphadenopathy, musculoskeletal symptoms, low body weight, and skin nodules.[24] 
A complex interaction of host and parasite factors including intensity of infection, 
chronicity, O. volvulus strain, geographic area of acquisition, host genetics, and 
individual immune response appear to influence disease manifestations.[18,21,25–27]  
Although intensity of infection often is related to particular sets of clinical 
manifestations, in particular prevalence of anterior eye disease, it does not fully account 
for differences in symptoms.[18,25]  Severe pruritus and extensive skin involvement can 
occur even with low parasite load, whereas individuals screened in endemic areas may be 
asymptomatic despite high microfilarial density.[18]  Prolonged infection, although not 
the sole determinant of clinical presentation, is linked to both the presence of eye disease 
and specific skin manifestations including depigmentation and atrophy.[21]  Early skin 
disease tends to be more inflammatory in nature, although inflammatory papules can be 
chronic, relapsing, or coexistent with other more chronic skin changes.[18]  
Regional variations in clinical manifestations are also apparent within 
bioclimactic African zones, the Americas, and the Middle East.  O. volvulus strains in 
West African savanna zones are associated with anterior segment ocular disease and a 
high prevalence of blindness, whereas West African forest strains have a propensity to 
cause skin disease and less frequently manifest with posterior segment eye 
involvement.[5]  Although some regions harbour only one predominate strain, overlap 
occurs throughout savannah-forest transition zones.  Patterns of disease in Central 
America are different than those observed in Africa, as endemic individuals in Guatemala 
and Mexico exhibit high rates of eye disease and numerous nodules, but less extensive 
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skin and lymph node involvement.[26]  The relative distribution of onchocercal nodules 
appears related to biting patterns of different regional Simulium subspecies.  Central 
American S. ochracium tends to bite on the upper half of the body, hence 
onchocercomata appear predominantly on the head and upper torso.  African S. 
damnosum is a low-biter, with nodules often noted on the legs and inguinal areas, in 
addition to the upper body in those infected as children.  Nodule location does not appear 
to be correlated with incidence of eye disease.  It is unclear to what extent geographic 
differences in clinical presentation are mediated by O. volvulus strain, strain-specific 
Wolbachia burden, differences in local Simulium vectors, and host genetics.[27–29]  
Finally, there is increasing evidence that the host’s ability to modulate 
inflammatory responses to O. volvulus is a significant determinant of disease phenotype. 
[30]  Human Leukocyte Antigen (HLA) genes, which are responsible for 
immunoregulation, differ in individuals with generalized disease, localized 
onchodermatitis, and putative immunity.[27,31]  A dampening of immune response to O. 
volvulus specific antigens occurs in chronically-infected endemic individuals, and may be 
related to in-utero or neonatal exposure to O. volvulus antigen.[30,32,33].  Mother-to-
child transmission of O. volvulus infection has occurred in endemic areas, and mothers 
with microfilaridermia secrete O. volvulus antigen in breast milk, providing potential 
means of early sensitization.[34,35]  
Perhaps the most striking illustration of the complex interplay between 
geographic, genetic, and host-parasite immunoregulation is the unique form of 
hyperreactive onchodermatitis known as Sowda.  Observed primarily in endemic 
populations in Yemen and Sub-Saharan Africa, Sowda presents as localized extensive 
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asymmetric skin disease with dark hyperpigmentation and pronounced regional 
lymphadenopathy.[36,37]  Despite its dramatic skin manifestations, Sowda is 
characterized by a remarkable paucity of microfilariae, a robust immune response 
consisting of eosinophilia and high filaria-specific antibodies, and a more severe post-
treatment reaction to ivermectin.[4,18,38] O. volvulus leads to a wide spectrum of clinical 
pathology through a variety of mechanisms, whose relative contributions are not yet fully 
established. 
Comparative disease manifestations in endemic and non-endemic populations 
With the rise in global migration and travel to remote destinations, filarial 
infections including onchocerciasis are increasingly diagnosed in non-endemic areas in 
immigrants, refugees and travelers.[39,40]  Disease manifestations of many parasitic 
infections, including filarial infections, differ markedly between life-long residents of 
endemic areas and temporary residents who acquire the disease while abroad.[39,41,42]  
Travelers infected with the related filarial parasite Loa loa display dramatic acute 
symptoms consisting of Calabar swellings and urticarial rash. [41–43]  This clinical 
phenotype is associated with immune hyperreactivity, as laboratory testing reveals 
marked eosinophilia, high parasite-specific immunoglobulins, and a shift towards Th2 
cytokines in response to mitogen stimulation of peripheral blood mononuclear cells 
(PMBCs).[41,43]  Despite a much higher burden of infection, endemic subjects with Loa 
loa or W. bancrofti display relative immune hyporesponsiveness, with comparatively few 
symptoms.[41,44] 
Endemic individuals (END) and temporary residents (TR) with onchocerciasis 
have not been extensively compared.  A 1994 study by McCarthy et al. noted significant 
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differences in clinical features, laboratory investigations, and immunologic markers 
between 20 TR and 21 END patients, although the assessment of the END was done in 
the field.[45]  Onchocercal eye disease and subcutaneous nodules were notably absent in 
TR patients.  Expatriates had a much lower burden of infection, as only 45% of infected 
TR had detectable microfiladermia compared with 100% of END (P < 0.01).  The mean 
microfilarial density was only 1 (range 1-3) in TR, compared with 43 (range 1-115) in 
endemic subjects. Interestingly, the pattern of immunologic findings was the opposite of 
that observed in Loa loa:  in O. volvulus, the END group had significantly higher 
eosinophil counts, and a more robust Th2 response with higher levels of IL-4 and IL-5 
cytokines produced by mitogen-stimulated PMBCs.  Unlike Loa loa, the differences in 
clinical manifestations between END and TR did not reflect a hyperresponsive state in 
the relatively immunologically-naïve TR group.  The authors posited that chronicity or 
parasite load more likely influenced disease manifestations.  However, this study had 
several notable limitations including small sample size, as well as potential confounding 
based on region of O. volvulus exposure and study setting.  TR patients were all infected 
in West and Central Africa, and were evaluated at the National Institutes of Health, 
whereas END patients acquired infection in Guatemala and were studied under field 
conditions. 
No other studies systematically compare END and TR with O. volvulus infection. 
Case series and clinical case reports provide insight into the clinical features of 
onchocerciasis in temporary residents, but provide no direct comparison to endemic 
individuals. Analyses performed by multi-national consortia of returned travelers 
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describe symptom timing and location of acquisition, but lack key details of the clinical 
assessment and relevant laboratory investigations. [39,40] 
In most case series, O. volvulus infection in TRs occurs with prolonged travel of 
at least 3 months, although travelers occasionally acquire onchocerciasis during short 
trips to highly endemic areas. [23,40,45]  In one multi-national study of returned travelers 
treated in subspecialty tropical disease clinics, three-quarters of Onchocerca-infected 
expatriates resided in the endemic area for less than 1 month. [39,46,47]  Almost all 
travelers acquire Onchocerca in Africa, while travel-associated infection is extremely 
rare in Latin America.[40,48]  Most studies and case reports describe delayed symptom 
onset ranging from months to years after leaving the endemic area, which is consistent 
with O. volvulus’ prolonged pre-patent period.[18,23,45,49]  However, the above multi-
national analysis of returned travelers found that two-thirds of nonendemic visitors 
became symptomatic within 1 month of return from the filaria-endemic area.  This 
finding suggests a shorter incubation period in TR than that previously described.[39]  
Significant delays in diagnosis are common, as medical practitioners in non-endemic 
areas are unfamiliar with onchocerciasis, and do not always relate symptoms to previous 
travel that occurred on average 1-3 years earlier.[18]  Only the study of patients referred 
to specialized travel clinics achieved consistently rapid diagnosis within 1 month of 
return from the endemic area.[39] 
Case series support McCarthy’s observations that TR commonly present with 
pruritus or papular rash.[49,50]  In 3 older cohorts of infected expatriates, pruritus was 
present in 68-89% of patients, and notably one-third had pruritus without evidence of 
rash.[49–51]  Pruritus was localized to only the lower back or buttocks in two-thirds of a 
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cohort of travelers to West and Central Africa.[51]  Rash was a presenting feature in half 
to two-thirds of patients, and was almost always pruritic and papular in morphology.[49–
51]  Few patients manifested lichenification or hyperpigmentation.[51]  Small case series 
describe dramatic acute unilateral limb edema, in particular of the upper extremity, as a 
presenting feature unique to expatriates.[5,46,47,52] 
The incidence of eye involvement in expatriates varies considerably in previous 
studies.  Expert observations, case reports, and small case series support the finding by 
McCarthy et al. that onchocercal eye disease rarely occurs in expatriate populations.  In a 
cohort of 22 infected expatriates returning from Cameroon, only 1 had evidence of 
punctate keratitis.[49]  However, two much larger historical expatriate cohorts challenge 
this assertion.  In a study of 95 Dutch expatriates with onchocerciasis conducted from 
1959-1971, Smit et al. found evidence of punctate keratitis in 13 of 59 travelers (22%) 
who received an ocular exam.[50]  Similarly, Woodruff et al. noted ocular findings in 
34% of a cohort of 76 patients, of which 72 were European expatriates.  In both studies, 
the lack of ocular symptoms did not preclude eye involvement.  Woodruff et al. found 
ocular microfilariae in 8 entirely asymptomatic patients, and only 23% of expatriates with 
punctate keratitis complained of eye symptoms.[51] 
Differences in duration of both exposure and infection might explain the 
drastically different burden of eye disease observed in more recent and comparatively 
historical TR cohorts.  The mean duration of residence in an O. volvulus endemic area 
was 11.6 years in the study by Woodruff et al., in which TR commonly had eye disease.  
By contrast, McCarthy observed no eye disease in TR, whose median exposure duration 
was only 2 years (range 20 months to 6 years).  Pryce et al. observed only 1 case of 
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punctate keratitis in a cohort exposed for a mean of 3 months (range 2 days to 15 
months).  Woodruff et al. asserted that exposure duration did not explain the high 
prevalence of eye disease in their patients, based on a shorter mean exposure of 8.2 years 
in the group with ocular disease, in comparison to the rest of the cohort.  Regardless, it is 
remarkable that the mean exposure in Woodruff et al. was longer than the maximum 
duration of residence in the two cohorts with low prevalence of eye disease.  
Furthermore, a subset of patients in the Woodruff et al. study acquired onchocerciasis in 
the pre-treatment era, and had prolonged untreated infection for 15-20 years.  This more 
closely parallels the chronic O. volvulus infection seen in endemic areas, and could 
therefore account for ocular involvement on par with local populations. 
High burden of infection was associated with onchocercal eye disease in the 
McCarthy et al. cohort, but microfilarial density did not predict eye involvement in older 
case series.  Woodruff et al. noted onchocercal eye disease in one third of lightly infected 
expatriates who had no evidence of dermal microfilariae.  Regional differences in O. 
volvulus strain could have contributed to the varying prevalence of eye disease observed 
between studies.  TR patients where almost exclusively infected in West or Central 
Africa in all four studies, but information about specific location of acquisition was not 
sufficiently precise to determine whether infections occurred in forest, savannah or 
forest-savannah mosaic zones.  In the two studies showing a low prevalence of eye 
disease, almost all TR were infected in either Sierra Leone or Cameroon.[45,49]  Older 
studies that observed substantial eye disease included expatriates infected primarily in 
Cameroon and Nigeria.  Prevalence of eye disease differs dramatically on a regional 
basis, such that it is not possible to draw conclusions about O. volvulus strain or 
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comparative infection intensity at the country-level.  For instance, even within Sierra 
Leone, community prevalence of O. volvulus eye disease ranges from 4% in typical forest 
zones to 75% in some savannah villages. [53,54] 
Lastly, the relative prevalence of asymptomatic O. volvulus infection in END and 
TR is not established.  On one hand, it is plausible that immunologically naïve expatriates 
without prior exposure to parasite antigen could experience more symptoms despite a 
much lower parasite load.  In a GeoSentinel analysis of returned travelers with filarial 
infection, patients born in filaria-endemic areas were 2.5 times more likely to be 
asymptomatic, as compared with non-endemic visitors (95% CI 1.07-5.81, P = 0.03).[39]  
However, this study included patients with all filarial infections, of which only 37% had 
onchocerciasis.  It is equally plausible that an extremely low parasite burden might cause 
no or minimal symptomatology.  Of 22 travelers diagnosed with onchocerciasis after an 
expedition to Cameroon, 9% were entirely asymptomatic.  The prevalence of 
asymptomatic O. volvulus in TR may have been even higher, as only 60% of cohort 
members received diagnostic testing.[49]  Similarly, 16 of 76 (21%) expatriates with 
microfilaridermia were asymptomatic in the study by Woodruff.  Interestingly, duration 
of exposure was longer in asymptomatic patients. 
Comparing immunologically naïve temporary residents and immune tolerant 
endemic populations provides a means of understanding how host-parasite interactions 
contribute to clinical pathology.  Few studies address this relationship in O. volvulus 
infection.  Although case series of O. volvulus infected travelers provide useful 
descriptive information, they offer no direct comparison with disease in endemic 
populations.  We aimed to systematically compare symptom timing, clinical presentation, 
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physical examination findings, and laboratory findings associated with O. volvulus 
infection in endemic individuals and temporary residents evaluated in a non-endemic 
tertiary care setting.  By characterizing disease manifestations in these two populations, 
we enable health care providers to better recognize diverse presentations of 
onchocerciasis in non-endemic areas.  Furthermore, we hoped to determine whether the 
paradigm of parasite-induced immune hyperresponsiveness in TR observed in Loa loa 
also holds true in onchocerciasis.  
METHODS 
Study subjects 
We included all patients with active Onchocerca volvulus infection evaluated by 
the Clinical Parasitology Section of the Laboratory of Parasitic Diseases, National 
Institute of Allergy and Infectious Diseases (NIAID) between 1976 and 2016.  Patients 
with active onchocerciasis had prior exposure to an O. volvulus-endemic region, and met 
at least one of the following criteria:  microfilaria visualized on “skin snips” or slit lamp 
examination; O. volvulus DNA detected by polymerase-chain reaction (PCR) testing of 
“skin snips”; positive antifilarial antibody testing, in addition to either a positive Mazzotti 
provocation test with diethylcarbamazine or a characteristic post-treatment reaction; or, 
positive antifilarial antibody testing in association with characteristic clinical symptoms 
of O. volvulus infection.[40,55]  All patients underwent “skin snips” and antifilarial 
antibody testing.  Only a subset of patients received Mazzotti provocation testing, which 
was historically used to aid in diagnosing patients with suspected infection, a normal slit 
lamp examination, and without evidence of dermal microfilariae.  Mazzotti provocation 
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testing was employed only in the earlier part of the cohort, and abandoned as a means of 
diagnosis in all patients evaluated at the NIH after the year 2000. 
Research Ethics 
The study was conducted under protocols approved by the NIAID Institutional 
Review Board, including the registered protocols NCT00001230 and NCT00001645.  All 
patients gave informed consent to participate.  Characteristics of a subset of temporary 
residents in this study were previously described.[45,55] 
 
 
Data collection and verification 
The lead author (AJS) retrospectively abstracted patient data from all available 
electronic medical records and paper charts, using a standardized electronic data 
abstraction form developed a priori (Appendix 1).   We recorded baseline demographic 
information, clinical signs and symptoms both at baseline and throughout the treatment 
course, routine and parasite-specific laboratory investigations, and antifilarial drug 
treatment.  We performed range edits and value checks to reduce the potential for data 
entry errors, and verified the accuracy of aberrant values. 
 
Patient Evaluation 
At study entry, all patients received a detailed medical history including travel 
history, and a complete physical examination. Clinical assessments were performed by 
NIAID Laboratory of Parasitic Diseases (LPD) physicians with experience in the 
diagnosis and management of parasitic infections.  Patient evaluations took place both in 
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the outpatient department and in the NIH inpatient unit.  Baseline evaluation included a 
dilated slit lamp examination performed by an ophthalmologist to exclude onchocercal 
eye disease.   
 
Laboratory investigations and parasitologic testing 
All patients received baseline laboratory investigations including a complete 
blood count with differential (WBC; normal range, 4.23 – 9.07 cells/mL), metabolic 
panel, urinalysis, and quantification of immunoglobulin G (IgG; normal range, 700–1500 
mg/dL), immunoglobulin M (IgM; 60–300 mg/dL), immunoglobulin A (IgA; 60–400 
mg/dL), and immunoglobulin E (IgE; 3–423 IU/mL).[41] 
Skin snips were performed on all patients to visualize dermal O. volvulus 
microfilariae by microscopy and/or to detect O. volvulus DNA through PCR.  Skin snips 
were performed using standard technique, using a Holth-type corneoscleral punch (Storz 
Instruments, St. Louis, Missouri) with samples taken from bilateral shoulders, hips and 
thighs.[45]  Patients received stool ova and parasite testing to identify coinfection with 
intestinal helminths, and urine ova and parasite testing for schistosomiasis when 
appropriate.  Patients with potential exposure to Loa loa underwent Nuclepore™ 
filtration (Pleasanton, California) of 1 mL of whole blood collected between 10 and 2 pm, 
and/or Loa loa PCR testing of whole blood.[41]  Patients with suspected Wuchereria 
bancrofti infection had Nuclepore™ filtration of whole blood collected between 10 pm 
and 12 am, and/or circulating antigen testing using the TropBio enzyme-linked 
immunosorbent assay (JCU Tropical Biotechnology Private Limited, Queensland, 
Australia).[41,56]  Additional laboratory and radiologic investigations, including testing 
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for non-parasitic coinfections such as HIV and hepatitis, were performed at the discretion 
of the treating physician. 
 
Parasite-specific immunoassays and recombinant antigen testing 
Testing for antibody response to a crude extract of filarial antigens and 
recombinant filarial-specific proteins was performed on patient sera stored at -80 degrees 
Celsius, and from the earliest study time-point available.  Antibody responses to Brugia 
malayi adult antigen (BMA) is measurable in all types of filarial infection because of its 
extensive antigenic cross reactivity with each of the filarial species; it is highly sensitive 
but not specific for O. volvulus infection.[45]  IgG and IgG4 antibodies to crude extracts 
of Brugia malayi adult antigen (BMA) were measured by ELISA using a standard 
technique as described elsewhere.[57,58]  A BMA-IgG >=14 μg/mL or BMA-IgG4 > 0 
ng/mL was considered a positive test.  Normal values were defined based on the upper 
99% confidence limits for 62 unexposed North Americans. [55,57] 
Antibody responses to the recombinant filarial antigens Wb-123, Ll-SXP-1, and 
Ov-16 are highly specific, but somewhat insensitive markers of infection with 
Wuchereria bancrofti, [59] Loa loa, [60] and Onchocerca volvulus respectively.[61]  We 
performed additional testing for serum antibodies to Wb-123, Ll-SXP-1, and Ov-16 using 
the Luminex™ platform (Bio-Plex MAGPIX Multiplex Reader; Bio-Rad).  For 
measurement of parasite-specific IgG4, we created 1:50 dilutions using 5 L of thawed 
patient serum and 245 L ELISA diluent (PBS Tween 1% BSA).  To measure IgG, we 
used a 1:1000 dilution using 10 L of the 1:50 dilution, combined with an additional 190 
L of ELISA diluent.  We aliquoted 100 µl each of IgG and IgG4 into separate 96-well 
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microplates (Greiner Bio-One).  We used a calibrated standard curve with known 
concentrations of antibody to recombinant parasite antigen. 
Parasite antigens Wb-123, Ll-SXP-1, and Ov-16 were purified exactly as 
previously described.[45,59,60]  Recombinant antigens were then chemically bound to 
magnetic Luminex™ beads using 10 mcg of each antigen and 25 million beads.  Bead 
sets were vortexed for 1 minute, then placed in an ultrasound bath for 1 minute.  We then 
diluted 4 L of each bead region (25 million beads/mL) in 5 mL of ELISA diluent, and 
added 50 L of bead dilution to each well (1000 beads/well) containing patient sera.  
Plates were then sealed, shaken at 500 rpm for 1 hour at room temperature, and washed 3 
times with 100 L of PBS Tween, with intervening 1 minute soaks (Biotek 405 
microplate washer). 
We then added 100 L of 1:000 dilution of biotin-conjugated IgG antibody 
(Jackson ImmunoResearch) to each IgG well, and biotin mouse anti-human IgG4 
(Southern Biotech) to each IgG4 well.  Plates were again shaken at 500 rpm for 1 hour, 
and washed as above.  We then added 50 L of 1:500 PE streptavidin (Jackson 
ImmunoResearch) per well.  Plates were shaken at room temperature for 15 minutes, and 
underwent a final wash.  An additional 80 L of ELISA diluent was placed in each well, 
plates were shaken for 10 minutes at 500 rpm at room temperature, and then read on the 
Luminex system.  Signal to noise ratios were interpreted based on a positive cut-off of 




Patients born in an Onchocera-endemic country were classified as endemic 
individuals (END), whereas those born in a non-endemic country were designated as 
temporary residents (TR).  We calculated duration of exposure for all patients with 
known dates of entry and exit into O. volvulus endemic countries.  For patients with 
multiple discrete visits to an endemic area, the duration of exposure represented the 
cumulative duration.  For the END group, the patient’s birth date was the date of entry.  
Time from exit to symptom onset was defined as the time between the last possible 
exposure to O. volvulus and the date of symptom onset.  This was calculated only for the 
subset of patients who became symptomatic after leaving the endemic area.  Time to 
diagnosis was defined as the time between symptom onset and diagnosis of O. volvulus 
infection, at the NIH or by another physician prior to the NIH baseline visit. 
Asymptomatic patients reported no characteristic symptoms of onchocerciasis, 
including pruritus, rash, visual disturbance, limb swelling, arthralgias, and nodules.   
Eosinophilia was defined as an absolute eosinophil count ≥ 500 cells/mL.  Leukocytosis 
was defined as a baseline white blood cell count > 9.07, which is the upper limit of the 
normal range for the Clinical Pathology Laboratory at the NIH. 
 
Statistical Analysis 
Categorical variables were compared using Fisher’s exact test.  Unless otherwise 
specified, continuous variables were analyzed using non-parametric testing with the 
Mann-Whitney U test.  When continuous data followed a normal distribution, the 
student’s t-test was used.  We used geometric means with 95% confidence intervals as 
measures of central tendency unless otherwise indicated.  
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Univariate and multivariate linear regression analyses were performed to evaluate 
the association between two key outcomes (absolute eosinophil count (AEC)  and BMA-
IgG4 level) and covariates including sex, duration of exposure to the endemic area, and 
coinfection with other helminth/filarial parasites.  The distribution of AEC and BMA-
IgG4 were positively skewed, therefore a logarithmic transformation was performed in 
the analysis.  Covariates were chosen based on the a priori hypothesis of potential 
confounding of the relationship between endemicity and the outcome of interest.  Testing 
for normality was performed using Quantile-Quantile plots, Kernel Density estimates, 
and the Shapiro-Wilk test.  Model residuals followed a normal distribution according to 
the Shapiro-Wilk test.  Colinearity was tested by calculating variance inflation factors, 
which were all less than 10.  The final multivariable regression model was analyzed 
based on robust resistant regression with bootstrapping performed with 1000 repetitions, 
to account for both non-normally distributed data and outliers.  Univariate logistic 
regression was performed to examine patient risk factors for onchocercal eye disease. 
Data were analyzed using Stata statistical software version 13 (StataCorp LP, College 





 We identified 76 patients with active O. volvulus infection, including 40 TR and 
36 END patients.  Fifteen END and 21 TR met inclusion criteria based on the presence of 
microfilariae or O. volvulus DNA in skin snips, 5 END and 24 TR had a positive 
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Mazzotti test/post-treatment reaction along with positive antifilarial serology, and 36 
END and 36 TR had symptoms of O. volvulus infection in addition to positive antifilarial 
serology. 
TR patients were more likely to be male (27/40 [68%]) compared with those in 
the END group (15/36 [42%], P = .037) (Table 1).  Median age was 33.3 years in the 
entire cohort (range 3.2-67.8 years), with no difference between groups (P = .12).  
Almost all END patients were African or African American (35/36 [97.2%]), while most 
TR were Caucasian (37/40 [92.5%], P < .001).  The majority of patients in both groups 
acquired infection in West or Central Africa (70/76 [92%]).  END patients were mainly 
infected in Cameroon (27/36 [75%]), while TR patients acquired infection throughout 
West and Central Africa, most commonly in Sierra Leone (14/40 [35%]).  The TR group 
included 25 Peace Corps volunteers, 5 missionaries, 4 research scientists, 2 healthcare 
workers, 2 children, and 2 occupational travelers.  O. volvulus infection occurred after a 
single period of exposure in 79% (16/76) of patients, with no major difference between 
TR and END groups (29/40 [72.5%] vs 31/36 [86.1%], P = .17).  The median duration of 
exposure to an O. volvulus-endemic area was significantly shorter in TR patients (28 




Concurrent parasitic infections were common in both groups.  Filarial coinfection, 
all with Loa loa, was present in 11.1 % of END and 5% of TR (P = 0.41).  No patient 
was infected with Wuchereria bancrofti or Mansonella spp.  Seven END (19.4%) and 3 
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TR (7.5%) were infected with at least 1 soil-transmitted helminth (P = .18).  The most 
common helminth coinfections were Strongyloides stercoralis (5 patients), hookworm (3 
patients), and Trichuris trichiura (1 patient).  One patient was coinfected with S. 
stercoralis and hookworm.  Two END (5.6%) and 1 TR (2.5%) had schistosomiasis (P = 
.6).  Other coinfections diagnosed at baseline included Giardia lamblia (2 TR, 2 END), 
chronic active hepatitis B (1 TR, 3 END), Hepatitis C (1 END), latent tuberculosis (2 
END), active pulmonary tuberculosis (1 END), and hyperreactive malarial splenomegaly 
(1 END).  No patient was diagnosed with HIV. 
 
Symptom timing and characteristics 
Most TR patients developed symptoms of O. volvulus infection after repatriation 
(29/35 [82.9%]) whereas the majority of END patients (18/29 [62.1%]) first noted 
symptoms prior to leaving the endemic area (Table 1).  In those who became 
symptomatic in the United States, the time interval between exiting the endemic area and 
symptom onset was prolonged in both groups:  TR manifested initial symptoms a mean 
of 15 months (SD 11.2) after leaving the endemic area, while END developed symptoms 
a mean of 33.5 months after immigration (SD 31.0, P = .096).  Although substantial 
delays in O. volvulus diagnosis occurred in both groups, END patients experienced more 
prolonged symptoms prior to diagnostic confirmation.  The median time from symptom 
onset to O. volvulus diagnosis was 6.3 months (IQR 2.8 – 15.2) in TR patients, and 26.9 
months (IQR 12.0 – 53.8) in the END group (P < .001). 
Symptoms prior to any filarial treatment were documented for all TR and 31 END 
(86.1%), and are described in Table 2.  Five TR patients (12.5%) were entirely 
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asymptomatic, whereas all END patients manifested at least one characteristic symptom 
of O. volvulus infection (P = .064).  The majority of both TR and END had pruritus (TR 
32/40 [80%] vs END 28/31 [90.3%], P = .33).  TR were more likely to describe rash 
(26/40 [65%]) compared with END (7/31 [22.6%], P = .001).  No TR complained of 
visual disturbance, which occurred in 12.9% of END patients (P = .032). Three TR 
(7.5%) and 3 END (9.7%) had arthralgias (P = 1.0).  Approximately 23% of patients in 
both groups described limb swelling (P = 1.0).  Of those who reported limb swelling, 
most (81%) had no evidence of Loa loa coinfection. 
 
Physical examination 
All patients received a physical examination at the baseline study visit (Table 3).  
Although similar numbers of TR and END had an abnormal dermatologic examination 
(TR 22/40 [55.0%] vs END 20/36 [55.6%], P = 1.0), skin manifestations were different 
in the two groups.  Papular onchodermatitis was present in 47.5% (19/40) of TR, but only 
in 2.7% (1/36) of END (P < .001).  Skin pigmentation changes occurred more frequently 
in END patients (15/36 [41.7%]), compared with the TR group (6/40 [15%], P = .01).  
Lichenification was observed more often in END patients (5/36 [13.9%]) than in TR 
(1/40 [2.5%]), but these differences were not statistically significant (P = .096).  One 
END patient in the series had evidence of hyperreactive onchodermatitis (Sowda) 
manifesting as papules, lichenification, and hypopigmentation. 
Onchocercal eye disease occurred almost exclusively in the END group.  Among 
END patients who received slit lamp examination, 7 (22.6%) had documented 
abnormalities consistent with sequelae of O. volvulus infection.  Only 1 TR (3.3%) had 
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evidence of onchocercal eye disease.  The difference approached statistical significance 
(P = .053). Slit lamp examination was not documented in 5 END and 10 TR patients.  
Specific ocular findings in the END group included corneal scarring in 4 patients, 
punctate keratitis in 2 patients, and sub-retinal scarring in 1 patient.  One TR had 
evidence of corneal scarring and retinal folds.  No patient in either group had posterior 
eye lesions. Univariate analysis revealed no difference in the odds of onchocercal eye 
disease based on sex (OR 0.7 [95% CI .15-3.1], P = .6) or region of exposure (West 
Africa vs. Central Africa, OR 3.9 [95% CI .4-36], P = .2).  The odds of onchocercal eye 
disease increased slightly with each additional year of residence in the endemic area (OR 
= 1.05 [95% CI 1.0 – 1.11], P = .04).  The TR patient with O. volvulus eye disease was 
the only person infected in East Africa after an unknown duration of residence. 
Unilateral limb edema was present in 1 END (2.8%) and 5 TR (12.5%, P = .2).  
Overall, 5 patients had unilateral upper extremity edema, and 1 had unilateral lower 
extremity edema.  Only 1 TR with upper extremity edema had concurrent filarial 
infection with Loa loa.  Similar proportions of END and TR had lymphadenopathy (END 
4/36 [11.1%] vs TR 7/40 [17.5%], P = .52) and subcutaneous nodules (END 6/36 
[16.7%] vs TR 4/40 [10%], P = .5).  All patients with documented subcutaneous nodules 
had only 1 or 2 palpable nodules.  Of the 4 TR patients with nodules, 3 had nodules on 
the upper body (head, epitrochlear, wrist), and 1 had trochanteric and iliac crest 
involvement.  In the END group, nodules were located on the upper chest wall or back in 
3 patients, upper limb in 1, lower limb in 1, and iliac crest/buttocks in 1 patient.  
Baseline physical examination took place prior to treatment at the NIH, however 
some patients had previously received antifilarial medications administered elsewhere. 
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There was no difference in the proportion of patients who had received antifilarial 
treatment within 5 years prior to the baseline physical examination (TR 10/40 [25%] vs 
END 13/36 [36.1%], P = .33). 
 
Laboratory investigations 
Table 4 describes baseline laboratory investigations for all patients who had not 
received antifilarial treatment within 5 years of study entry.  Absolute eosinophil counts  
(AEC) were similar for both TR (GM 797.5 cells/mL [95% CI 502.1-1266.7]) and END 
(GM 763.7 cells/mL [95% CI 432.9 - 1347.1], P = .97) (Figure 1). Multivariable 
regression analysis also revealed no difference in AEC comparing END and TR, 
adjusting for sex, duration of residence in the onchocerca-endemic area, and presence or 
absence of helminthic coinfection (P = .2).  None of these variables were independently 
associated with AEC in our cohort.  Only two-thirds of patients in each group had 
eosinophilia.  There was no difference in eosinophil percentage (END 13.6 [95% CI 8.6 - 
21.7] vs TR 11.8 [95% CI 8.1-17.3], P = .47). The TR group had a higher geometric 
mean white blood cell count (7.3 x 10
3
/mL [95% CI 6.4 - 8.5]) than the END group (5.7 x 
10
3
/mL [4.9 - 6.6], P = .003), although there was no difference in the proportion of 
patients with leukocytosis (2/21 [9.5] in END and 4/28 [14.3%] in TR, P = .69). 
END patients had higher baseline polyclonal IgG (GM 1968 mg/dL [95% CI 1590 
- 2436]) compared with the TR group (GM 1233 [95% CI 1147 - 1324], P = .001).  
Polyclonal IgG was elevated in 80% of END, but in only 4.5% of TR (P < .001). 
Polyclonal IgE was also significantly higher in END compared with TR (GM 1309 
IU/mL [95% CI 652 - 2628] vs 251 [95% CI 139 – 451], P < .001); however, there was 
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no difference in the proportion with a polyclonal IgE above the normal range (END 15/20 
[75%] vs TR 11/23 [47.8%], P = .12). 
 
Parasite-specific serologic testing 
All but 3 patients (2 TR, 1 END) had an elevated BMA-IgG or BMA-IgG4 (Table 
5).  Geometric mean BMA-IgG concentrations were similar in END (158 g/mL [95% 
CI 100 - 250]) and TR groups (175 g/mL [95% CI 11 2 - 275], P = .68); however, the 
IgG-specific percentage of the total IgG (BMA-IgG/total IgG) was significantly higher in 
TR than END (1.7% [95% CI 1.0- 2.8] vs 0.8% [95% CI .4-1.5], respectively, P = .04) 
(Figure 2).  Patients in the END group were more likely to have positive testing for 
BMA-IgG4 (89% vs 62.5%, P = .015), and among those who tested positive, END 
patients had significantly higher BMA-IgG4 levels (7916 ng/mL [95% CI 5167 - 12128]) 
compared with TR (2241 ng/mL [95% CI 1171 - 4290], P = .005). There was no 
significant difference in BMA-IgG4 comparing END and TR after adjusting for sex, 
duration of exposure, and presence of filarial coinfection (P = .7).  Although duration of 
exposure was positively associated with BMA-IgG4 level on univariate analysis (P = 
.03), this effect was not observed after multivariate regression (P = .9).  A higher 
proportion of END patients were positive for Ov-16 IgG4 (END 18/36 [50%] vs TR 
10/40 [25%], P = .03), but there was no difference between groups in geometric mean 
Ov-16 IgG4 (END 676 ng/mL [95% CI 343 - 1333] vs TR 618 ng/mL [95% CI 218 -
1750], P = .84). 
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DISCUSSION 
We evaluated 40 temporary residents and 36 endemic individuals with 
onchocerciasis who underwent rigorous diagnostic testing in a non-endemic tertiary care 
setting.  Although there was substantial overlap in the presentation of onchocerciasis in 
TR and END, our study revealed several important differences between these two groups.   
Both END and TR were equally likely to present with skin manifestations, but the nature 
of skin involvement differed: the TR group had more papular dermatitis, whereas END 
had pigmentation changes which are typically associated with more chronic 
inflammation.  Eye disease occurred in only 1 TR, whereas 23% of END patients had 
ocular involvement based on slit lamp examination. There was a trend towards a higher 
prevalence of asymptomatic infection in TR patients, of which 12.5% had no 
characteristic symptoms of O. volvulus.   
Unlike Loa loa, differences between END and TR infected with O. volvulus did 
not appear to be related to an eosinophil-mediated immune hyperresponsive state in TR.  
Our study found no difference whatsoever between groups in either absolute eosinophil 
count or eosinophil percentage.  We observed the same result after controlling for sex, 
helminth coinfection, and duration of exposure to the endemic area, which were therefore 
not confounding variables.  Our results differed from those of McCarthy et al., who 
observed significantly higher absolute eosinophil count in END (GM 2634 cells/mL 
[95% CI 268 - 7342]) compared with TR (GM 1056 cells/mL [95% CI 250 -3245], P < 
0.05).  Notably, the geometric mean eosinophil count in END patients in the McCarthy 
study was well above the upper limit of the 95% confidence interval for our END group.  
Discordant results might be attributed to the very different composition of the END 
groups.  We evaluated infected endemic individuals presenting in a non-endemic setting, 
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on average years after leaving the endemic area, whereas McCarthy et al. looked at END 
patients within an endemic setting.  END patients in the earlier study had ongoing O. 
volvulus exposure, and presumably also a much higher prevalence of geohelminth 
infection, both of which might raise eosinophil count.[45] 
Differences in END and TR may instead be linked to infection chronicity.  END 
subjects had a significantly longer duration of exposure and time to diagnosis, which 
implies more prolonged untreated infection.  Onchocercal eye disease was associated 
with longer exposure duration in the END group.   END patients also had higher levels of 
BMA-IgG4, and more frequent Ov-16 IgG4 positivity, both of which likely reflect more 
chronic disease.  Several other measured and unmeasured variables may also have 
contributed to differences observed between groups.  END and TR differed based on both 
sex and race.  Microfilarial densities were not well documented in many patients with 
microfilaridermia, so we could not evaluate the impact of parasite burden.  We also could 
not determine whether there were clinically important between-group differences in O. 
volvulus strain.  Almost all patients in both groups acquired onchocerciasis in Africa, but 
more TR patients were infected in West Africa (Sierra Leone), and most END acquired 
O. volvulus in Central Africa (Cameroon).  O. volvulus strains prevalent in West African 
forest zones are known to cause less eye disease.  However, there is substantial intra-
country O. volvulus strain variability within forest, savannah and transition zones, and 
this degree of regional geographic information was not available in our cohort.[29] 
Although we could not establish the causal mechanism responsible for differences 
between END and TR, our findings have important implications for clinicians in non-
endemic countries.  First and foremost, physicians must consider O. volvulus based on 
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relevant epidemiologic exposure alone, as one eighth of TR were entirely asymptomatic. 
These patients were typically referred for evaluation after an incidental finding of 
eosinophilia, or were screened based on similar exposure to a known O. volvulus case.  
The substantial number of asymptomatic expatriates also supports an approach of active 
case-finding within cohorts of travelers with similar epidemiologic exposures.[49]  
Interestingly, there was a trend towards a higher prevalence of asymptomatic infection in 
TR patients compared with the END group.  Screening programs in endemic areas 
commonly identify asymptomatic infection in endemic areas, but all END patients in our 
cohort had at least one symptom of onchocerciasis.[5]  This unexpected finding may be 
related to health-care seeking behaviour of foreign-born populations in a non-endemic 
setting.  Time to diagnosis was substantially longer in the END group compared with TR, 
which may reflect lack of access to healthcare or prioritization of other needs in the 
context of recent immigration. 
Our study also has implications for the timing of recommended physician 
evaluation post-travel or immigration.  O. volvulus symptoms manifested months to years 
after return from the endemic area.  Most TR presented between 6 to 12 months after 
return, and therefore symptoms would be missed at a one-time screening medical 
examination for tropical infections that typically occurs between 1 to 2 months after 
repatriation, if at all.  For TR, a second travel-focused medical examination occurring 1 
year after return might increase detection of O. volvulus.  The time-lag was even longer 
for END patients, who presented for medical care a median of ~3 years after immigration 
to the United States.  Education of primary care providers serving populations from 
endemic areas might be a more effective strategy in this population, as the longer time to 
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symptom onset requires serial evaluation in the first 5 years after immigration.  The 
above interventions could reduce the unacceptably long median time to diagnosis of 6 
months in TR and 2 years in END.  
The lack of eye disease in TR in our study corroborates findings of McCarthy et 
al., recent case series of returned travelers, and expert opinion.[5,45]  The low prevalence 
of eye disease in our TR group compared with historical cohorts may reflect differences 
in infection chronicity or intensity.  TR in our series spent a median duration of 2 years in 
O. volvulus endemic areas, and had untreated infection for approximately 6-12 months 
before a diagnosis was established.  In historical cohorts, TR populations with a high 
prevalence of onchocercal eye disease spent a median of 8-11 years in O. volvulus 
endemic areas and had chronic untreated infection more similar to our END 
population.[50,51]  Unless exposure is very prolonged, TR patients appear unlikely to 
develop eye disease.  Unfortunately, duration of exposure was unknown for the sole TR 
in our series with O. volvulus eye involvement.  A 23% prevalence of onchocercal eye 
disease in our END group strongly supports routine slit lamp examination in migrants 
from highly endemic areas, in particular those who report visual symptoms. 
Although eye disease is rare in TR, we found that unilateral limb swelling is a 
fairly common presenting symptom and should prompt consideration of O. volvulus. 
[46,47]  One fifth of TR reported limb swelling, and one eighth of TR had objective 
unilateral limb edema on baseline physical examination.  Limb swelling in 1 TR could 
have been related to Loa loa coinfection, but the remaining 4 TR patients were not 
infected with Loa loa or Wuchereria bancrofti.  In contrast to prior studies, we observed 
skin nodules on physical examination in equal proportions of END and TR.  Prior case 
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series specifically remark on the absence of nodules in expatriates. [45]  Although 
physical examination in our series was performed by experienced physicians with 
training in parasitic diseases, nodules palpated on exam were not confirmed to be 
onchocercomata based on biopsy, excision, or imaging.  We could therefore not exclude 
other causes such as fibromas, lymph nodes, or ganglion cysts. 
Finally, our study has implications for laboratory testing for O. volvulus in 
returned travelers and migrants from endemic areas.  We found that a normal eosinophil 
count cannot be used to rule out O. volvulus infection in either END or TR.  One-third of 
O. volvulus-infected patients had a normal eosinophil count.  In common clinical 
practice, BMA-IgG4 is the only test performed to screen for suspected filarial infection.  
In our study, relying on BMA-IgG4 alone to exclude O. volvulus infection would have 
missed 10% of infections in END and 40% of infections in TR.  BMA-IgG4 is linked to 
more chronic infection, and may not be elevated in TR presenting in the acute setting. 
Ov-16 IgG4 was not a sensitive test and was elevated in only half of END and one 
quarter of TR, which is a noteworthy limitation when this test is employed as a screening 
tool.     
 
Limitations 
Although this is the largest study to date directly comparing O. volvulus infection 
in endemic individuals and temporary residents, onchocerciasis is a rare diagnosis in a 
non-endemic setting and the number of study subjects was small.  Some patients in both 
groups had received prior treatment with antifilarial drugs, which can affect both 
eosinophil count and parasite-specific antibody response.  In comparing laboratory 
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investigations, we therefore looked exclusively at the patient subset who had not been 
treated within 5 years, which further reduced our sample size. 
There is also the potential for selection bias, as patients referred for evaluation 
and treatment at the National Institutes of Health may differ from the broader population 
with O. volvulus in the United States.  In the earlier part of the cohort, difficult access to 
antifilarial drugs to treat onchocerciasis mitigated the potential for selection bias, as most 
patients were treated in highly specialized tertiary care centers similar to the NIH.  The 
McCarthy et al. study published in 1994 examined a subset of TR included in our  cohort, 
and determined this to be a representative sample of patients with O. volvulus in the 
United States.[45]  The FDA approval of ivermectin in 1998 allowed for widespread use 
without requiring an Investigational New Drug application through the Center for 
Disease Control.  Patients treated at the NIH in the more recent part of the cohort could 
therefore potentially represent either more refractory or severe cases than those treated in 
the broader community setting. 
Although patient assessment occurred prospectively according to established NIH 
research protocols for the evaluation and treatment of parasitic infections, we abstracted 
patient information retrospectively using existing medical records in which 
documentation was at times incomplete. We were therefore unable to systematically 
collect data pertaining to microfilarial density, which was not always recorded in the 
patient chart at the time of skin snips.  All patients received a full physical examination 
performed by an experienced Laboratory of Parasitic Diseases physician, however there 
was still the potential for observer variability particularly in the description of O. volvulus 
skin manifestations.  Although an ophthalmologist performed a slit lamp examination for 
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all patients as part of the routine study protocol, documentation of the assessment was 
missing for a total of 10 TR and 5 END, whose examinations were mostly likely normal.  
There remained a trend towards fewer ocular manifestations in TR, but with complete 
data the difference between groups would have most likely reached the P < .05 threshold 
for statistical significance. 
 
Conclusions 
The global burden of onchocerciasis continues to decrease as a result of vector 
control programs and mass drug administration campaigns, which are now entering the 
elimination phase in many countries.[7]  Onchocerciasis however remains a major public 
health problem in areas of West Africa that are co-endemic for Loa loa.  Ivermectin mass 
drug administration cannot be broadly implemented in co-endemic areas, due to the risk 
of precipitating encephalopathy in individuals with high levels of Loa loa microfilaremia.  
Although point-of-care diagnostics for Loa loa may ultimately resolve this problem, both 
endemic populations and travelers are still at risk of infection.[62,63] 
Our study describes differing clinical presentations of onchocerciasis in migrants 
and travelers.  Unlike Loa loa, differences in END and TR are not eosinophil mediated, 
and could instead be related to infection chronicity.  Comparison of Th1 and Th2 
cytokine production in response to parasite antigen could shed light on the mechanism 
underlying the clinical differences we observed.  The duration of treatment required to 
achieve clinical cure in a non-endemic setting is also unknown.[55]  Further evaluation of 
clinical, eosinophil and parasite-specific antibody response to treatment in our patient 




Table 1.  Demographic characteristics of Endemic Individuals and Temporary 
Residents with Onchocerciasis 
 
 
Abbreviations: IQR, interquartile range; SD, standard deviation;  
 
a
 West/Central Africa included Benin, Gambia, Guinea, Ghana, Ivory Coast, Liberia, Nigeria, 
Senegal, Sierra Leone, Togo, Angola, Cameroon, Central African Republic, Congo, Democratic 
Republic of Congo, Equatorial Guinea, and Gabon; East Africa included Burundi; Central/South 
America included Guatemala and Venezuela.
 
b 
The most common intestinal helminths were Strongyloides stercoralis (5 patients), Hookworm 
(3 patients), and Trichuris trichiura (1 patient).  One patient was coinfected with S. stercoralis 
and Hookworm. 
c
 Included infection with other filarial parasites, soil-transmitted helminths, and schistosomiasis
 
d 
Unable to determine for 6 END and 7 TR patients. 
e
 Excluded 4 asymptomatic TR. Symptom onset location was unknown for 1 TR and 7 END.  
f 
Calculated using the student’s t-test, based on 10 END and 22 TR patients.  
g





n = 36 
Temporary Residents 
n = 40 P Value 
Female, No. (%) 21 (58.3) 13 (32.5) .037 
Age, years, median (IQR)  36.9 (26.7-45.2) 30.3 (27.5-38.6) .12 
Race, No. (%) 
Caucasian  


























Loa loa coinfection, No. (%) 4 (11.1) 2 (5.0) .41 




7 (19.4) 3 (7.5) .18 
Helminth coinfection, No. (%)
c
 12 (33.3) 6 (15) .1 
Duration of residence in 




373 (295-520) 28 (24-48) <.001 
Symptom onset in endemic area,  
No. (%)
e 
18 (62.1) 6 (17.1) <.001 
Time to symptom onset after 




33.5 (31.0) 15 (11.2) .096 
Time from symptom onset to 




26.9 (12.0-53.8) 6.3 (2.8-15.2) <.001 
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No. (%) P value 
Asymptomatic 0 (0) 5 (12.5) .064 
Pruritus 28 (90.3) 32 (80) .33 
Rash 7 (22.6) 26 (65) .001 
Visual disturbance 4 (12.9) 0 (0) .032 
Limb swelling 7 (22.6) 9 (22.5) 1.0 
Arthralgias 3 (9.7) 3 (7.5) 1.0 
 
a 








 Baseline physical examination performed at the National Institute of Health first study visit, 
irrespective of prior treatment. 
b 
Slit lamp examination findings were not documented in 5 END and 10 TR patients.  
c 
1 END patient had unilateral upper extremity edema.  In the TR group, 4 patients had unilateral 








No. (%) P value 
Skin manifestations    
     Papules 1 (2.7) 19 (47.5) < .001 
     Pigmentation changes 15 (41.7) 6 (15) .011 
     Lichenification 5 (13.9) 1 (2.5) .096 
Onchocercal eye disease
b
 7 (22.6) 1 (3.3) .053 
     Punctate keratitis 2 (6.5) 0 (0) .49 
     Corneal scarring 4 (12.9) 1 (3.3) .35 
     Subretinal scarring 1 (3.2) 0 (0) 1.0 
Limb edema, unilateral
c
 1 (2.8) 5 (12.5) .2 
Lymphadenopathy 4 (11.1) 7 (17.5) .52 
Subcutaneous nodules 6 (16.7) 4 (10) .5 
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Table 4.  Baseline Laboratory Investigations, in Patients with No History of 
Antifilarial Treatment Within 5 years  
 
 
Abbreviations: AEC, absolute eosinophil count; CI, confidence interval; GM, geometric mean; 
IgE, immunoglobulin E; IgG, immunoglobulin G; WBC, white blood cell.  
 
a
 Included 21 END and 28 TR patients  
b
 Included 20 END and 23 TR patients 
 
c




GM (95% CI) 
Temporary Residents 
GM (95% CI) P Value 
AEC, cells/mL
a
 763.7 (432.9-1347.1) 797.5 (502.1-1266.7) .97 
Eosinophils, % 
a
 13.6 (8.6-21.7) 11.8 (8.1-17.3) .47 
Eosinophilia, No. (%)
 a





 5.7 (4.9-6.6) 7.3 (6.4-8.4) .003 
Leukocytosis, No. (%)
 a
   2 (9.5) 4 (14.3) .69 
Polyclonal IgE, IU/mL
 b
 1309 (652-2628) 251 (139-451) < .001 




15 (75) 11 (47.8) .12 
Polyclonal IgG, mg/dL 
c
 1968 (1590-2436) 1233 (1147-1324) .001 




12 (80) 1 (4.5) <.001 
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Table 5.  Baseline Parasite-specific Serologic Testing, in Patients with No History of 
Antifilarial Treatment Within 5 Years 
 
 
Abbreviations: BMA, Brugia malayi adult antigen; CI, confidence interval; GM, geometric mean; 
IgG, immunoglobulin G; Ov, Onchocerca volvulus  
 
a 
Included 18 END and 22 TR patients 
b
 Based on first available serum independent of prior treatment 
c
 Included 15 END and 13 TR patients 
d
 Included 12 END and 18 TR patients 
e






GM (95% CI) 
Temporary Residents 
GM (95% CI) P Value 
BMA-IgG, g/mL
 a
 158.1 (100-250) 175.0 (112-275) .68 




34 (94.4) 37 (92.5) .28 
BMA-IgG4, ng/mL
c
 7916 (5167-12128) 2241(1171-4290) .005 




31 (89) 25 (62.5) .015 




0.77 (0.4-1.5) 1.7 (1.0-2.8) .038 
Ov-16 IgG4, ng/mL
 e
 676 (343-1333) 618 (218-1750) .84 




18 (50) 10 (25) .033 
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FIGURE 1:  Differences between Endemic Individuals and Temporary Residents in 
Absolute Eosinophil Count, White Blood Cell Count, and Immunoglobulin Levels  
 
 
   
 
 




Figure 1.  Horizontal lines represent the geometric mean.  Data points within the shaded area lie within the 
normal range of the assay.  Abbreviations:  AEC, absolute eosinophil count; END, endemic individuals; Ig, 




FIGURE 2:  Differences between Endemic Individuals and Temporary Residents in 





Figure 2:  Horizontal lines represent the geometric mean.  Dashed lines represent the upper limit of 
detection of the assay.  Abbreviations:  BMA, Brugia malayi adult antigen; END, endemic individuals; Ig, 
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